A biopharma diagnostics executive discusses how proteomics technologies are leveraged in their oncology portfolio for understanding disease biology and mechanisms of resistance. Their definition of next generation proteomics involves new technologies for ultra-sensitive, highly plexed, and single cell level applications, but these are still early for clinical applications. The stakeholder lists Luminex, MSD, and Quanterix as top companies in the multiplex immunoassay space, mass spec for metabolite profiling, and is also very familiar with Olink. The top three applications of next generation proteomics in the stakeholder's research are therapeutic response monitoring, biomarker discovery, and single cell proteomics. Therapeutic response monitoring involves monitoring pharmacodynamic and pharmacokinetic responses, cytokine release storms, and immune reactivity in clinical oncology. Biomarker discovery and single cell proteomics are applied for earlier stage R&D.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.